LOS ANGELES--(BUSINESS WIRE)--Cynvenio Biosystems, Inc., the pioneer in LiquidBiopsy technology for the genomic analysis of tumor cells from whole blood in support of cancer precision medicine strategies, today announced a partnership with newly launched Cure Forward, a patient activation company based in Cambridge, Massachusetts.
Cure Forward provides a secure, web-based platform for patients to share their individual genomic test results and access comprehensive disease information, discover treatment options and learn about available clinical trials to help in their fight against cancer, and eventually other diseases.
Cynvenio’s ClearID™ test, powered by its CLIA-certified LiquidBiopsy® technology, detects tumor cells recovered from a standard blood draw based on the presence of cancer-associated DNA mutations. By identifying the specific genomic mutations driving the disease, ClearID can unlock relevant treatment options and help clinical trial recruiters speed patient enrollments for clinical trials. Currently, the ClearID test is used to assess breast, prostate and colorectal cancers.
“Cure Forward combines genomic technology and business model innovation to improve patient care while overcoming inefficiencies that slow drug development and limit overall patient participation in clinical trials,” said André de Fusco, Cynvenio’s CEO. “We are enthused to partner with Cure Forward to substantially improve this paradigm.”
Based on a Harris Interactive survey of nearly 6,000 cancer patients, only about 15 percent were aware that participation in clinical trials was even a treatment option for them. With Cure Forward, patients are given direct access to their healthcare data – in this case, knowledge from the ClearID test results – and they are empowered with practical tools to understand their disease and take action - including an individualized educational library, a marketplace-driven trial matching system, and the ability to interact with other patients.
“The barriers to personalized medicine are too high for too many patients. We help people find innovative testing options like the ClearID test from Cynvenio, and then use those results to be more effective champions of their own care,” said Martin Naley, CEO of Cure Forward. “We are excited to work with Cynvenio to open the doors of genomic medicine so that more patients can find insights and options that shape their care.”
About Cure Forward
Cure Forward is a patient activation company bringing together science, community and education, giving patients unprecedented ability to utilize their molecular test data. Through the company’s website, patients can connect with relevant information, treatment options, and other similar patients. Cure Forward makes personalized healthcare accessible and approachable for patients and caregivers, activating their potential for cure or action against their disease. Cure Forward was incubated and launched by Apple Tree Partners, a leading healthcare venture capital firm headquartered in New York City. For more information, visit www.cureforward.com.
About Cynvenio Biosystems, Inc.
Cynvenio is a commercial stage clinical diagnostics company that leverages its proprietary LiquidBiopsy® multi-template technology for the molecular characterization of tumor cells from a standard blood draw. Commercial labs and research institutions are powered by Cynvenio’s LiquidBiopsy platform, which includes automated instrumentation, consumables/reagents, patients sample kits, and bioinformatics for sequencing rare cell populations. Oncology practices and individual physicians can also access the LiquidBiopsy system with zero upfront investment by ordering the ClearID™ blood test from Cynvenio’s CLIA lab or its clinical partners. ClearID and LiquidBiopsy are cornerstones in the emerging field of genomic peripheral blood monitoring. They are used to rapidly assess patients’ evolving mutations in support of precision medicine strategies. ClearID is reimbursable in the United States.
LiquidBiopsy® and ClearID™ are registered trademarks of Cynvenio Biosystems, Inc.